The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yep, I'm afraid you're right. They are not interested in making 200-300% over a few months, they'd rather make 5-10% over a day or two. Of course, they don't always catch it right.
I’m holding tight. Expecting TR1 updates to follow from the majors. Would be silly to sell at such a low price.
$165m license contract / a float of 175m shares is surely a market valuation of 94 Cents or 85p a share alone!
We are fulfilled with shorters desperate to make some quick wonga. They should realise soon that its time to go. They dissappear with every next trade, then nice and steady rise.
Thats my plan, exactly that. Plus I think about transferring my pension into sipp and make it top choice.
At 5/6/7p makes no difference when the intention is to hold for 12 plus months.
The key is to accumulate a decent holding, then switch off.
500K shares may cost circa £30K now, but I suspect will be worth many multiples in 12 months.
Pop them in the ISA for Tax free gains.
Its a sin to short this share, GL LTH'S
Looking forward to when the Americans see the presentation updates. The share flew when they were able to trade.
£18k buy just showed up. Nice to see others see the prospects!
the wider market is beginning to catch on to the massive upside here.
It is estimated that one in every one hundred children worldwide have ASD (1% of the child population). The market is massive and there are currently no other approved treatments.
GLA.
EVG presentation - Great update -
Summary - "very confident indeed" of getting the full $160million royalty from the ASD deal, only potential non side affect treatment in a $4 billion US market. Transformative for the company, fast tracked and earning money from day one - clearly working on other deals - legal advise that they are still inside (more deals IMO) - also given away biggest holders are adding post news
It will also be posted on YouTube.
Interestingly, I’m watching a presentation on YouTube on EVgen from 2 months ago, well worth watching too, it demonstrates just how much they have in the pipeline across numerous disciplines.
The newsflow will be constant over the next 12 months, and if there’s one thing the market likes, is newsflow!!
The presentation also demonstrates why The BoD have been advised by their legal department that they cannot BUY at the moment.
Licensing Deal with Stalicla and Clinical Progress Update
* The company had 9m in cash reserves as of 31 March 2022
* Therefore, the company has a cash runway to at least Q4 2022; and indeed, well into 2025 if Stalicla milestones are included
* There is currently no approved treatment for ASD (Stalicla SFX-01 to solve this issue)
* Stalicla deal is worth £165 million
* America alone has 1.7M people with ASD (this is seen as Evgen's main market)
* Looking for similar deals to advance breast cancer research
Answers from Q+As
* The board could not buy stock during the negotiations regarding the Stalicla deal, for fear of insider trading, although they would like to buy more stock in the future
* The board have been in negotiations with Stalicla from January 2022
* A takeover was deemed to be unlikely as the product has not reached market yet
* The larger intuitional investors are in for the long hall (AXA since 2015 and Octopus since 2021)
What's not to like?
GLA.
I'm waiting on money clearing to buy more. This stock is a steal at these prices!
12-Oct-22 13:52:07 6.17 291,620 Buy* 5.90 6.10 17.99k
Some nice buys
They said that the presentation will be shortly available for playback from the presentation website. Deffo worth a watch.
Really impressed with the presentation. The board clearly have an excellent background and are realistic on goals and milestones, not ramping with false promises and expectations like some management in other PLC’s.
Good to know that major investors such as AXA have been involved since 2015, so says to me that the company is a very secure investment despite all the troubles in the world.
Also highly reassured by the comments on the Directors not being able to buy shares currently to prevent accusations of insider trading owing to their recent contract awards. Plus, they aren’t issuing confetti shares and are passionate about their science, not shareholder funds, so prospects of share dilution unless a major comes in are slim, which is a breath of fresh air!
Brilliant outlook for this company
Have to agree ii buying in open market, strong backers and royalties on top of £160M for a business that has £9m Cash
Multibagger all day as he said double Derisked
any one have the recording for the presentation
This is worth many multiples of current SP.
There will be institutions buying in days and weeks ahead. Going to hold through 2023. Perhaps will derisk a bit at 20p.
All IMHO DYOR
Best
Happy
I'm listening to it. The SP is a steal, and yet it's hardly moving. I predict it'll triple bag+ from here in months
I’m watching it, Their Legal advisors suggest Directors/BOD etc are unable to buy stock at the moment!!
We know what that means!!!
Is anyone listening to the presentation? The CEO is saying that the autism treatment is demonstrably proved already. They are very confident that they will achieve £165 million of milestones. It's a transformative transaction. They have a two year run way on funding right into 2025. They're looking for partners for the breast cancer treatment and they've reiterated the new phase one cancer assessment for brain tumours.
The whole panel sound really positive and really confident about SFX01 and the varied potential of the drug for meeting the needs of vast, multi-billion pound markets.
Big hint theyre open to discussion at the right price...